Gadolinium Makers Issue Warnings that its Contrast Agents Increase the Risk of NSF

Jamie Sheller

Attorney
(866) 735-1102 Ext 475

0 CommentsPrint ArticleSubscribe

At the request of the FDA, Gadolinium makers -- Bayer, GE-Healthcare, Bracco, and Mallinckrodt, notified Healthcare providers that its gadolinium-based contrast agents increase the risk of NSF in certain patients. Gadolinium contrast agents are used by medical providers to enhance the quality of MRI scans. The five gadolinium-based contrast agents are commonly known as: Magnevist, Omniscan, OptiMARK, MultiHance, and ProHance. NSF is a disease of the skin and connective tissue. It causes significant thickening of the skin to the extent that joint mobility becomes limited.

Based upon reported adverse events, those individuals most likely at risk were people who suffered from kidney malfunction or advanced renal failure, liver transplantation patients (preoperative & postoperative), and people suffering from chronic liver disease. If you or your loved one has been injured by a gadolinium based product, you may be entitled to receive compensation for your pain and suffering. Drug manufacturers are required to ensure the safety and efficacy of their products before marketing them. Failure to adequately measure drug safety is considered to be negligent and grounds for personal injury litigation. The attorneys at Sheller, P.C. would be happy to speak with you about your legal rights. For more information about this story check: http://www.fda.gov/medwatch/safety/2007/safety07.htm#Gadolinium

For more information on this subject, please refer to Drugs, Medical Devices, and Implants.